Bleeding complications related to warfarin treatment: A descriptive register study from the anticoagulation clinic at Helsingborg Hospital

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 1, 2014, Pages 98-104

  Navgren, Monica ^a   Forsblad, Johan ^a   Wieloch, Mattias ^b,c  

^a HELSINGBORG HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Atrial fibrillation; Bleeding complications; Spontaneous reporting; TTR; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ABDOMINAL BLEEDING; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT TOOL; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HEMATOMA; HEMATURIA; HEMOPTYSIS; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MUSCLE BLEEDING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; SWEDEN; TIME IN THERAPEUTIC RANGE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; ADULT; CHEMICALLY INDUCED; COMPARATIVE STUDY; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; PROSPECTIVE STUDY; REGISTER; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84902363873     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1011-z     Document Type: Article

References (33)

1. Cavallini A, Fanucchi S (2008) Warfarin-associated intracerebral hemorrage. Neurol Sci 29:266-268
2. Nationella riktlinjer för hjärtsjukvård. Socialstyrelsen 2008. ISBN: 978-91-85483-96-9
3. Socialstyrelsen. Socialstyrelsens riktlinjer för vård av blodpropp/ venös tromboembolism 2004. Faktadokument och beslutsstöd för prioriteringar. http://www.socialstyrelsen.se/Lists/Artikelkatalog/ Attchments/10270/2004-102-3-20041023.pdf
4. Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use. A prevalent adverse effect resulting in regulatory action. Arch Intern Med 167(13):1414-1419 (Pubitemid 47052441)
5. Wiederman CJ, Stockner I (2008) Warfarin-induced bleeding complications-clinical p resentation and therapeutic options. Thromb Res 122(Suppl. 2):13-18
6. Go A, Hylek E, Phillips K et al (2001) Prevalence of diagnosed atrial fibrillation in adults. National implications of rytm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (Atria) study. JAMA 285:18
7. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment, American college of chest physicians evidence-based clinical practise guidelines (8th edition). Chest 133:257-298
8. Gottsäter A, Svensson PJ (2010) Klinisk handläggning av venös tromboembolism. Studentlitteratur AB, Lund
9. Steiner T, Rosand J, Diringer M (2006) Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 37:256-262 (Pubitemid 43732088)
10. Conolly SJ, Pogue J, Eikelboom J et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029-2037
11. Wieloch M, Själander A, Frykman V et al (2011) Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding and thromboembolic complications from the national quality registry Auricula. Eur Heart J 32:2282-2289
12. Palaretti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Lancet 348: 423-428 (Pubitemid 26267872)
13. Wan Y, Heneghan C et al (2008) Anticoagulation control and prediction of adverse effects in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1:84-91
14. Camm AJ, Lip G, DeCaterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719-2747
15. White HD, Gimber M, Feyzi J et al (2007) Comparizon of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239-245
16. Jones M, McEwan P, Morgan C et al (2005) Evaluation of the pattern of treatment, level of anticoagulation control and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 91:472-477 (Pubitemid 40432773)
17. Connolly SJ, Ezekowitz MD et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139-1151
18. van Walraven C, Jennings A, Oake N et al (2006) Effect of setting on anticoagulation control: a systematic review and metaregression. Chest 129:1155-1166
19. Wallentin L, Yusuf S, Ezekowitz MD et al (2010) Efficiacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975-983
20. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692-694 (Pubitemid 41647882)
21. Rosendaal FR, Cannegieter CC, van der Meer FJ et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236-239 (Pubitemid 23069000)
22. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457
23. Abdelhafiz AH, Wheeldon NM (2004) Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulant clinic. Clin Ther 26:1470-1478 (Pubitemid 39582715)
24. Ost D, Tepper J, Mihara H et al (2005) Duration of anticoagulation following venous thromboembolism: a metaanalysis. JAMA 294:706-715 (Pubitemid 41159290)
25. McConeghy K, Bress A, Wing C (2013) Reports of bleeding-related fatalities with dabigatran and warfarin: an analysis using the Food and Drug Administration adverse events reporting system. American College of Cardiology 2013 Scientific Sessions, San Francisco, 10 March 2013, Abstract 914-8
26. FDA drug safety communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran) http://www.fda.gov/Drugs/ DrugSafety/ucm326580.htm
27. Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med. doi: 10.1056/NEJMp1302834. http://www.nejm.org
28. Weber JCP (1984) Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. Adv Inflamm Res 6:1-7
29. Landerfeld SC, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315-328
30. Landerfeld CS (1989) Major bleeding in outpatients treated with warfarin: incidence and predicition by factors known at the start of outpatient therapy. Am J Med 87:144-152
31. Van der Meer FJM, Rosendaal FR et al (1993) Bleeding comlications in oral anticoagulant therapy. Arch Intern Med 153: 1557-1562
32. Pisters R, Lane RA, Nieuwlaat K et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with AF. The Euro Heart Survey. Chest 138(5):1093-1100
33. Lip Gy, Frison L, Halperin JL et al (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED score. J Am Coll Cardiol 57(2):173-180